We found that under basal conditions, SHP2 cancer mutations weaken the observed potency of SHP099 when compared with SHP2WT, and that the inhibitory potency of SHP099 generally scales inversely with the basal phosphatase activity of the cancer mutant (Fig. 4 and Supplementary Table 3). The gene discussed is PTPN11; the disease is cancer.